BridgeBio Oncology Therapeutics (BBOT) vs Vanda Pharmaceuticals (VNDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vanda Pharmaceuticals (VNDA) has outperformed BridgeBio Oncology Therapeutics (BBOT) over the past year, losing 14.3% versus a loss of 71.6%. BridgeBio Oncology Therapeutics is the larger company by market cap ($274.2 million vs $273.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBOT | VNDA |
|---|---|---|
| Share price | $3.42 | $4.53 |
| Market cap | $274.20M | $273.90M |
| 1-day change | -0.58% | -0.66% |
| YTD return | -72.68% | -48.30% |
| 1-year return | -71.56% | -14.29% |
| 5-year return | — | -75.39% |
| Forward P/E | — | 22.65 |
| EPS (TTM) | $-0.07 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.87 | $9.94 |
| 52-week low | $3.27 | $4.27 |
| Distance from 52-week high | -77.00% | -54.43% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +617.84% | +159.38% |
| Average volume | 468.83K | 969.16K |
| Shares outstanding | 80.17M | 60.46M |
| Employees | 88 | 533 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VNDA has outperformed BBOT by 57.3 percentage points over the past year.
- The two companies sit in different sectors: BridgeBio Oncology Therapeutics in Health Care and Vanda Pharmaceuticals in Healthcare.
About BridgeBio Oncology Therapeutics
BBOT stock →BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About Vanda Pharmaceuticals
VNDA stock →Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Healthcare · Biotechnology · 533 employees
BBOT vs VNDA FAQ
Which is bigger, BridgeBio Oncology Therapeutics or Vanda Pharmaceuticals?
BridgeBio Oncology Therapeutics (BBOT) is larger, with a market capitalization of $274.20M compared with $273.90M for Vanda Pharmaceuticals (VNDA).
Which stock has performed better over the past year, BBOT or VNDA?
VNDA returned -14.29% over the past 12 months, compared with -71.56% for BBOT (price return, excluding dividends). Past performance does not predict future results.
Are BridgeBio Oncology Therapeutics and Vanda Pharmaceuticals in the same industry?
No. BridgeBio Oncology Therapeutics is in the Health Care sector, while Vanda Pharmaceuticals is in Healthcare.